Defining and treating high-risk multiple myeloma. - Wikidata - awgldk - TriplyDB

Defining and treating high-risk multiple myeloma.

Defining and treating high-risk multiple myeloma.

http://www.wikidata.org/entity/Q38564926

about

Towards Stratified Medicine in Plasma Cell Myeloma Advances in understanding prognosis in myeloma.Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.Carfilzomib Triple Combination Therapy: A Review in Relapsed Multiple Myeloma.ADP-ribosylation factor 1 (ARF1) takes part in cell proliferation and cell adhesion-mediated drug resistance (CAM-DR).Primary Plasma Cell Leukemia: Identity Card 2016.Current Review on High-Risk Multiple Myeloma.Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis.Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy.Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo.The effect of novel therapies in high-molecular-risk multiple myeloma.Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the Chronic Malignancies Working Party of the EBMT.Nanotherapeutics for multiple myeloma.Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASP Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.

P2860

Q28074994-F29E1894-AB7C-47E5-B2B8-50172E56E947 Q30244061-2F05C12D-B1DF-4839-9561-4B97BACF1749 Q31154933-870812BA-5F37-49DC-894D-BF0D4F3A7CE1 Q33430690-CE2CEC53-7F39-403D-9B6F-C90E25FB9330 Q38714809-252AB2C9-CF93-4B75-8DAE-D18BC851D6CF Q38781794-AECD7259-66D4-444F-B74A-F40455130D28 Q38895167-ED6AE84B-357E-4CA4-93B6-9207724C04A5 Q38932298-9DE688BD-5CD8-4C23-AFEE-1944C9B2E0B4 Q39518931-A283130C-6A61-4BDE-8154-6B51B486A0D7 Q41346803-7819AAD6-6F1F-44AF-966E-4D4D384433A9 Q41545464-8E7FAA3C-C475-4112-8F3A-3A105C36A5A1 Q46640442-29F302D7-EDA9-4017-96D0-7CDCC8A9666E Q47375990-3FF48622-E6AD-454A-B337-27C3C722437F Q50057730-B9C7AFE8-D7C6-4046-BB94-79415FCFA4B0 Q50118881-C8D595CE-4039-4F94-942F-F0195F591919 Q52559684-40208878-C758-45C2-B530-A0E5E2413F48 Q52609413-1F5E9CD5-B34A-41EC-861E-7B72B76B6FE5 Q52663601-247F716A-4310-44FA-9C21-9E97943E6B0C

P2860

Defining and treating high-risk multiple myeloma.

http://www.wikidata.org/entity/Q38564926

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Defining and treating high-risk multiple myeloma.

@en

type

label

Defining and treating high-risk multiple myeloma.

@en

prefLabel

Defining and treating high-risk multiple myeloma.

@en

P1433

Q38564926-ECF35DFB-4632-4EE0-BCAA-8DB184D87179

P1476

Q38564926-D287D459-B7B6-46AD-A0B7-E6BFC5AF8AAC

P2093

Q38564926-4FBF146C-CD1A-46CA-A2C4-445ADA766F57

Q38564926-74366E76-8D9A-4F88-823E-D90312E263C5

Q38564926-89AF007F-36D7-4909-822F-377B95CF6716

Q38564926-9264DB60-4458-4F76-9354-2456C923BCFC

Q38564926-96665BFA-994B-4489-AE4A-EFB77ED0E9E1

P2860

Q38564926-0555A11F-B352-4852-BEBD-D758BCBA0770

Q38564926-05D0537A-D5DF-46EA-8BC4-23C7CD0D80D7

Q38564926-07B48E0F-4A3B-49E3-93F8-971992FFA69E

Q38564926-08DAEC5C-5B53-47E3-8679-6C3DB082A640

Q38564926-0EAEE200-89AD-4BCF-BB52-7ED0036C77C6

Q38564926-1308B73B-A6F8-48C4-8345-128C4D30A861

Q38564926-1315972D-C4E4-4241-B0B4-3D139CCDA5EB

Q38564926-18EBCF5E-CA2F-43FC-8686-3955529E432C

Q38564926-19A81ADD-C246-4B29-92FC-27BD448C888B

Q38564926-1DD18035-2EEE-458B-85BD-A1E5EF68E085

P2888

Q38564926-65A4E42E-8DDC-453E-807B-AAFC246C7779

P304

Q38564926-ABDA09EF-A490-45AA-9901-9C82A089DB3E

P31

Q38564926-E549D210-BF7D-49CC-8C05-8ADE2D2FE857

P356

Q38564926-DA52723A-CE6B-4928-A473-8F0EA557CECD

P433

Q38564926-08DB1D86-4DD3-48AB-8979-99C36811CEEB

P478

Q38564926-C06942FE-96C2-418A-A299-0FCAB27C9E89

P577

Q38564926-434E7A61-11BC-4825-87A2-56939AA15439

P6179

Q38564926-76A13B37-352B-4DF9-BDD2-ACE3190057B1

P698

Q38564926-379D2195-CE55-44FC-AA61-BE62D2F2084D

P356

P1433

P1476

Defining and treating high-risk multiple myeloma.

@en

P2093

J S Miguel

http://www.w3.org/2001/XMLSchema#string

M Bhutani

http://www.w3.org/2001/XMLSchema#string

M-V Mateos

http://www.w3.org/2001/XMLSchema#string

P Rodriguez-Otero

http://www.w3.org/2001/XMLSchema#string

S Z Usmani

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic significance of copy-number alterations in multiple myeloma

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.

Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents.

A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma.

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

International staging system for multiple myeloma.

Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.

P2888

P304

2119-2125

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2015.209

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1018475875

http://www.w3.org/2001/XMLSchema#string

P698

26265183

http://www.w3.org/2001/XMLSchema#string